David B. Bharucha

David B. Bharucha

Auto-generated profile, based on publicly available information

David B. Bharucha

Milestone Pharmaceuticals Inc, Charlotte, NC, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
BSBruce S. Stambler
Bruce S. Stambler
BCBenoit Coutu
Benoit Coutu
JIJames E. Ip
James E. Ip
BMBlandine Mondésert
Blandine Mondésert
APA. Shekhar Pandey
A. Shekhar Pandey
ACA. John Camm
A. John Camm

1 April 2025 in International Journal of Toxicology
Verified
Journal Article
Open access
AAAlexis Ascah
Alexis Ascah
JMJean-Pierre Moreau
Jean-Pierre Moreau
SASimon Authier
Simon Authier
DBDavid B. Bharucha
David B. Bharucha
DWDouglas Wight
Douglas Wight
Paroxysmal supraventricular tachycardia (PSVT) is a common cardiac arrhythmia associated with substantial health care burden. Etripamil, a fast-acting non-dihydropyridine calcium channel blocker developed for intranasal self-administration, is currently under investigation for acute treatment of PSVT episodes. A novel two-phase study design was used to test a series of five doses of intravenous etripamil (0, 0.025, 0.05, 0.15, and 0.3 mg/kg) in conscious cynomolgus monkeys. The cardiovascular effects (e.g., blood pressure and ECG recordings) were assessed during the first phase, and the pharmacokinetic profile was characterized during the second phase. Animals were dosed remotely to avoid the stress of intranasal dosing and minimize the impact of dose administration on measurements. Results were compared with findings from subsequent intranasal studies in cynomolgus monkeys and humans. Etripamil decreased systolic blood pressure and increased heart rate proportionately in a dose-dependent manner. Etripamil also induced dose-dependent increases in the PR interval. At a dose of 0.3 mg/kg (the highest dose), the mean highest PR prolongation from baseline during 20 minutes after dosing was 27.38%. Systemic exposure to etripamil increased in a dose-dependent manner. Mean area under the curve from administration to when drug was no longer present (AUC 0–∞ ) values ranged from 179 to 2364 ng • min/mL, peak plasma concentration ranged from 13.2 to 176 ng/mL, and mean half-life ranged from 12.3 to 20.8 minutes (Figure 1). Results were consistent with data from subsequent intranasal preclinical and clinical studies. Intravenous etripamil demonstrated the desired targeted pharmacokinetic and pharmacodynamic profiles in conscious cynomolgus monkeys.